Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Lymphoma, Non-Hodgkin 16Myelodysplastic Syndromes 15Leukemia, Myeloid, Acute 15Leukemia, Lymphocytic, Chronic, B-Cell 15Hodgkin Disease 15Lymphoma, Mantle-Cell 14Multiple Myeloma 13Waldenstrom Macroglobulinemia 12Graft vs Host Disease 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma 11Leukemia 11Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 10Sarcoma 9Myeloproliferative Disorders 9Burkitt Lymphoma 9Tuberous Sclerosis 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Primary Myelofibrosis 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms 6Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myelomonocytic, Chronic 6Congenital Abnormalities 6Breast Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma, Large-Cell, Anaplastic 5Lymphangioleiomyomatosis 5

Interventions

pralsetinib 2pembrolizumab 2Brentuximab Vedotin 2Bevacizumab 2ribociclib 1fosaprepitant 1Sunitinib 1Sirolimus 1Radiotherapy, Image-Guided 1Plicamycin 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Genistein 1Gemcitabine 1Erlotinib Hydrochloride 1Dexamethasone 1Cisplatin 1Carboplatin 1Aprepitant 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Germ Cell and Embryonal × Sirolimus × Clear all
NCT01962896 2019-02-26

A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

University of Texas Southwestern Medical Center

Phase 2 Terminated
4 enrolled 6 charts

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡